5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

e14584 Background: The safety profile and efficacy of the Folfirinox regimen as first-line chemotherapy in metastatic pancreatic cancer (MPC) was previously reported in a phase II study (Conroy, J Clin Oncol, 2005:1228). We retrospectively studied the feasability and the efficacy of this regimen as second-line therapy in our institution. Methods: Twenty-seven patients (pts) with MPC were treated by Folfirinox between January 2003 and November 2009. The recommended schedule was oxaliplatin 85 mg/m2 d1 + irinotecan 180 mg/m2 d1 + LV 400 mg/m2 d1 followed by 5-FU 400 mg/m2 bolus d1 and 2,400 mg/m2 46h continuous infusion biweekly. Results: Pts characteristics: M/F = 13/14; median age = 63 years (45-83). Ten had a complete resection of primary tumor, 6 had a adjuvant chemotherpy by gemcitibine, and 4 had an adjuvant radiotherapy concomittant with capecitabine. All patients had a progressive disease after first-line chemotherapy by gemcitabine. Safety: A total of 167 cycles were delivered, with a median number...